Editorial: Exploring novel approaches to small molecule kinase inhibitors in cancer treatment

Editorial: Exploring novel approaches to small molecule kinase inhibitors in cancer treatment

Saved in:

Bibliographic Details
Main Authors:	Anna Carbone, Rafael M. Couñago, Cristian O. Salas, Alessandra Moltalbano
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-02-01
Series:	Frontiers in Chemistry
Subjects:	cancer kinases kinase inhibitors small molecules antitumor agents
Online Access:	https://www.frontiersin.org/articles/10.3389/fchem.2025.1559849/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Editorial: Exploring small molecule inhibitors in cardiovascular and cerebrovascular diseases
by: Basveshwar Gawali, et al.
Published: (2025-02-01)

Protein kinase inhibitors as targeted therapy for glioblastoma: a meta-analysis of randomized controlled clinical trials
by: José Pinto-Fraga, et al.
Published: (2025-02-01)

Did selective kinase inhibitors change the management of patients with radioiodine-refractory thyroid cancer?
by: Tommaso Porcelli, et al.
Published: (2025-02-01)

Unveiling the Anti-Angiogenic Potential of Small-Molecule (Kinase) Inhibitors for Application in Rheumatoid Arthritis
by: Fatemeh Khodadust, et al.
Published: (2025-01-01)

Two Cysteines in Raf Kinase Inhibitor Protein Make Differential Contributions to Structural Dynamics In Vitro
by: Hyun Sang Cho, et al.
Published: (2025-01-01)

Janus kinase inhibitor treatment for inflammatory diseases: excess or no excess risk of venous thromboembolism?
by: Yachar Dawudi, et al.
Published: (2025-01-01)

An Anaplastic Lymphoma Kinase-positive Inflammatory Myofibroblastic Tumor with Rapidly Acquired Resistance to First-line Anaplastic Lymphoma Kinase Inhibitor: A Case and Literature Review
by: Shu-Cheng Wu, et al.
Published: (2024-01-01)

Janus kinase inhibitors and biologics for treatment of livedoid vasculopathy: a systematic review
by: Yu Liu, et al.
Published: (2025-12-01)

Increased risk of Pneumocystis jirovecii colonization in rheumatoid arthritis patients on biologics and Janus kinase inhibitor
by: Ya-Chun Huang, et al.
Published: (2025-02-01)

Cyclic Peptides as Protein Kinase Modulators and Their Involvement in the Treatment of Diverse Human Diseases
by: Lorena Martínez-Alcantar, et al.
Published: (2024-12-01)

The tyrosine kinase inhibitor lenvatinib is oxidized by rat cytochromes P450 and affects their expression in rat liver
by: Indra Radek, et al.
Published: (2024-09-01)

4,6-Disubstituted pyrimidine-based microtubule affinity-regulating kinase 4 (MARK4) inhibitors: synthesis, characterization, in-vitro activity and in-silico studies
by: Ashanul Haque, et al.
Published: (2025-01-01)

Comparative safety profile of tyrosine kinase inhibitors in NSCLC: a network meta-analysis of hypertension and thrombotic risks
by: Mingming Tan, et al.
Published: (2025-01-01)

FDA-approved kinase inhibitors: a promising therapeutic avenue for traumatic brain injury
by: Dezhu Gao, et al.
Published: (2024-12-01)

HPK1 kinase inhibitor: a sufficient approach to target HPK1 to modulate T cell activation in cancer immunotherapy compared with degraders
by: Qin Wang, et al.
Published: (2025-02-01)

Role of Janus Kinase inhibitors in the management of pulmonary involvement due to Long COVID-19 disease: A case control study
by: Pawan Kumar Singh, et al.
Published: (2023-07-01)

Effects of Food on the Pharmacokinetics and Safety of HA121-28 Tablet, a Novel Multi-Targeting Tyrosine Kinase Inhibitor, in Healthy Chinese Subjects: A Phase I Clinical Trial
by: Liu Y, et al.
Published: (2025-01-01)

Screening and identification of host signaling pathways for alleviating influenza-induced production of pro-inflammatory cytokines, IP-10, IL-8, and MCP-1, using a U937 cell-based influenza model
by: Si Chen, et al.
Published: (2025-01-01)

Vascular Endothelial Growth Factor (VEGF) Family and the Immune System: Activators or Inhibitors?
by: Cristina Maria Failla, et al.
Published: (2024-12-01)

An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors
by: Russell J. Schilder, et al.
Published: (2025-03-01)

Use of thymidine kinase 1 autoantibody, thymidine kinase antigen, extracellular protein kinase A autoantibody, and C‐reactive protein for early detection of malignant tumors in dogs
by: Yoonhee Kim, et al.
Published: (2025-01-01)

Research Progress in Small-Molecule Detection Using Aptamer-Based SERS Techniques
by: Li Zheng, et al.
Published: (2025-01-01)

Efficacy and safety of Janus kinase inhibitors in the treatment of psoriasis and psoriatic arthritis: An analysis of evidence from 2014 to 2022
by: Jiao Wang, et al.
Published: (2025-02-01)

Editorial: Advances in immunotherapy of hepatic-biliary-pancreatic cancers, volume II
by: Hu Jiaming, et al.
Published: (2025-01-01)

Long term efficacy and safety of Lorlatinib in ALK-positive non-small cell lung cancer: A case report
by: Jialin Qian, et al.
Published: (2025-03-01)

Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
by: Ichiro Yamauchi, et al.
Published: (2025-01-01)

Treatment advances in Vitiligo: An Updated Review
by: Ishrat Binti Ismail, et al.
Published: (2025-01-01)

Rechallenge therapy versus tyrosine kinase inhibitor (TKI) for advanced metastatic colorectal cancer: a retrospective study
by: Chenming Liu, et al.
Published: (2025-02-01)

Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis
by: Huibin Yang, et al.
Published: (2025-12-01)

A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality
by: Jain Nem Kumar, et al.
Published: (2024-03-01)

Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis
by: Peter Youssef, et al.
Published: (2025-01-01)

Antiedemic Effect of the Myosin Light Chain Kinase Inhibitor PIK7 in the Rat Model of Myocardial Ischemia Reperfusion Injury
by: Dmitry L. Sonin, et al.
Published: (2025-01-01)

Real‐World Study of EGFR‐TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuation in Patients With EGFR‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study
by: Kei Sonehara, et al.
Published: (2025-01-01)

Impact of First- and Second-Generation Tyrosine Kinase Inhibitors on the Development of Graft-Versus-Host Disease in Individuals with Chronic Myeloid Leukemia: A Retrospective Analysis on Behalf of the Polish Adult Leukemia Group
by: Ugo Giordano, et al.
Published: (2025-01-01)

Exploratory study on the efficacy of topical pan-JAK inhibitor in ocular and skin GVHD in a sclerodermatous GVHD mouse model
by: Shinri Sato, et al.
Published: (2025-01-01)

Refractory Chronic Hand Eczema Responds to Oral Upadacitinib
by: Nada Alghamdi, et al.
Published: (2025-01-01)

Effects of Switching to Netarsudil/Latanoprost Fixed Dose Combination from Various Latanoprost Regimens: The Phase 4 MORE Study
by: Bacharach J, et al.
Published: (2025-01-01)

The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute lymphoblastic leukemia
by: Xiaoxia Wu, et al.
Published: (2024-09-01)

Oxidative and adhesive responses of human neutrophils to nitrovasodilators in vitro: the role of protein kinases
by: Magdalena Klink, et al.
Published: (2003-01-01)

Real-World Experience with CDK4/6 Inhibitors in the First-Line Palliative Setting for HR+/HER2− Advanced Breast Cancer
by: Ram Patel, et al.
Published: (2025-01-01)